Predicted protein targets (top 2)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DYRK1A | Q13627 | 20/20 | 1.00 |
| ▸ | DYRK1B | Q9Y463 | 18/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10446906 | 1.00 | DYRK1A (1.00) | DYRK1ADYRK1B | |
| SCHEMBL11949583 | 0.93 | DYRK1A (0.87) | DYRK1ADYRK1B | |
| SCHEMBL10446879 | 0.93 | DYRK1A (0.87) | DYRK1ADYRK1B | |
| SCHEMBL10446845 | 0.93 | DYRK1A (1.00) | DYRK1ADYRK1B | |
| SCHEMBL10446534 | 0.92 | DYRK1A (1.00) | DYRK1ADYRK1B | |
| SCHEMBL10446967 | 0.91 | DYRK1A (0.88) | DYRK1ADYRK1B | |
| SCHEMBL10446992 | 0.90 | DYRK1A (0.82) | DYRK1ADYRK1B | |
| SCHEMBL10446929 | 0.90 | DYRK1A (0.85) | DYRK1ADYRK1B | |
| SCHEMBL10446530 | 0.89 | DYRK1A (0.86) | DYRK1ADYRK1B | |
| SCHEMBL10323097 | 0.88 | DYRK1A (0.79) | DYRK1ADYRK1B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12295955-B2 | TTP phosphorylation for the identification of personalized medicines | KING FAISAL SPECIALIST HOSPITAL & RESEARCH CENTRE (SA) | 2025-05-13 | — | — | US | disclosed |
| WO-2025069009-A1 | ROCK2 INHIBITORS IN THE TREATMENT OF OBESITY | GRAVITON BIOSCIENCE BV (NL) | 2025-04-03 | — | — | WO | disclosed |
| WO-2025069008-A1 | THERAPY FOR TREATING TYPE 1 DIABETES USING ROCK2 AND DYRK1 INHIBITORS | GRAVITON BIOSCIENCE BV (NL) | 2025-04-03 | — | — | WO | disclosed |
| US-20240390406-A1 | PHOSPHORYLATED TRISTETRAPROLIN AS A BIOMARKER AND THERAPEUTIC TARGET FOR ANTIAGING DRUGS | KING FAISAL SPECIALIST HOSPITAL & RESEARCH CENTRE (SA) | 2024-11-28 | — | — | US | disclosed |
| EP-4467978-A1 | PHOSPHORYLATED TRISTETRAPROLIN AS A BIOMARKER AND THERAPEUTIC TARGET FOR ANTI-AGING DRUGS | King Faisal Specialist Hospital & Research Centre (SA) | 2024-11-27 | — | — | EP | disclosed |
| US-20240352418-A1 | METHOD FOR PRODUCING MULTINUCLEATED MEGAKARYOCYTE WITH ENHANCED PLATELET PRODUCTION CAPABILITY, METHOD FOR PRODUCING PLATELETS, METHOD FOR PRODUCING PLATELET PREPARATION, AND METHOD FOR PRODUCING BLOOD PREPARATION | MEGAKARYON CORPORATION (JP) | 2024-10-24 | — | — | US | disclosed |
| EP-4342982-A1 | METHOD FOR PRODUCING MULTINUCLEATED MEGAKARYOCYTE WITH ENHANCED PLATELET PRODUCTION CAPABILITY, METHOD FOR PRODUCING PLATELETS, METHOD FOR PRODUCING PLATELET PREPARATION, AND METHOD FOR PRODUCING BLOOD PREPARATION | Megakaryon Corporation (JP) | 2024-03-27 | — | — | EP | disclosed |
| CN-117500913-A | Method for producing multinucleated megakaryocyte having enhanced platelet production ability, method for producing platelets, method for producing platelet preparation, and method for producing blood preparation | 株式会社美加细胞 | 2024-02-02 | — | — | CN | disclosed |
| WO-2023230592-A1 | METHODS OF IDENTIFYING GENETICALLY-ANCHORED MOLECULAR SIGNATURES FOR DISEASE AND TREATMENTS THEREOF | THE GENERAL HOSPITAL CORPORATION (US) | 2023-11-30 | — | — | WO | disclosed |
| US-20230310437-A1 | TTP PHOSPHORYLATION FOR THE IDENTIFICATION OF PERSONALIZED MEDICINES | KING FAISAL SPECIALIST HOSPITAL & RESEARCH CENTRE (SA) | 2023-10-05 | — | — | US | disclosed |
| WO-2023140846-A1 | COMBINATION CANCER THERAPY WITH DYRK1 INHIBITORS AND INHIBITORS OF THE RAS-RAF-MEK-ERK (MAPK) PATHWAY | FELICITEX THERAPEUTICS, INC. (US) | 2023-07-27 | — | — | WO | disclosed |
| US-20230226061-A1 | COMBINATION CANCER THERAPY WITH DYRK1 INHIBITORS AND INHIBITORS OF THE RAS-RAF-MEK-ERK (MAPK) PATHWAY | FELICITEX THERAPUETICS INC (US) | 2023-07-20 | — | — | US | disclosed |
| US-11648251-B2 | TTP phosphorylation as a biomarker in targeted therapy | KING FAISAL SPECIALIST HOSPITAL & RESEARCH CENTRE (SA) | 2023-05-16 | — | — | US | disclosed |
| US-20230126310-A1 | COMPOSITIONS FOR CORONAVIRUS INFECTION TREATMENT AND/OR PREVENTION | FRAUNHOFER GES FORSCHUNG (DE) | 2023-04-27 | — | — | US | disclosed |
| WO-2022265117-A1 | METHOD FOR PRODUCING MULTINUCLEATED MEGAKARYOCYTE WITH ENHANCED PLATELET PRODUCTION CAPABILITY, METHOD FOR PRODUCING PLATELETS, METHOD FOR PRODUCING PLATELET PREPARATION, AND METHOD FOR PRODUCING BLOOD PREPARATION | 株式会社メガカリオン | 2022-12-22 | — | — | WO | disclosed |
| WO-2022149615-A1 | CULTURE MEDIUM FOR EXPANSION CULTURE OF NEPHRON PROGENITOR CELL, METHOD FOR PERFORMING EXPANSION CULTURE OF NEPHRON PROGENITOR CELL, AND METHOD FOR PRODUCING KIDNEY ORGANOID | 国立大学法人京都大学 | 2022-07-14 | — | — | WO | disclosed |
| US-20220110941-A1 | COMBINATIONS FOR THE TREATMENT OF NEOPLASMS USING QUIESCENT CELL TARGETING AND INHIBITORS OF MITOSIS | FELICITEX THERAPEUTICS, INC. | 2022-04-14 | — | — | US | disclosed |
| US-20220110940-A1 | COMBINATIONS FOR THE TREATMENT OF NEOPLASMS USING QUIESCENT CELL TARGETING WITH EGFR INHIBITORS | FELICITEX THERAPEUTICS, INC. | 2022-04-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230226061-A1 | COMBINATION CANCER THERAPY WITH DYRK1 INHIBITORS AND INHIBITORS OF THE RAS-RAF-MEK-ERK (MAPK) PATHWAY | KRAS, BRAF, RAF1 | DYRK1A 12/4885DYRK1B 10/4885 |
| US-20220110940-A1 | COMBINATIONS FOR THE TREATMENT OF NEOPLASMS USING QUIESCENT CELL TARGETING WITH EGFR INHIBITORS | EGFR, ERBB2, ERBB3 | DYRK1A 552/4885DYRK1B 644/4885 |
| US-20220110941-A1 | COMBINATIONS FOR THE TREATMENT OF NEOPLASMS USING QUIESCENT CELL TARGETING AND INHIBITORS OF MITOSIS | BUB1B, BUB1, CCNB1 | DYRK1A 999/4885DYRK1B 1125/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.